Valuation: Orion Oyj

Market Cap 14.34B 16.06B 13.19B 11.98B 22.69B 1,506B 23.26B 158B 62.91B 806B 60.3B 59.01B 2,539B P/E 2026 *
23.7x
P/E 2027 * 20.2x
Enterprise Value 14.22B 15.93B 13.09B 11.88B 22.51B 1,493B 23.07B 157B 62.4B 800B 59.8B 58.52B 2,518B EV / Sales 2026 *
6.75x
EV / Sales 2027 * 5.79x
Free-Float
90.18%
Yield 2026 *
1.9%
Yield 2027 * 2.25%
1 week+3.04%
Current month+2.11%
1 month+23.69%
3 months+29.35%
6 months+52.17%
Current year+60.82%
1 week 98
Extreme 98
103.4
1 month 79.2
Extreme 79.2
103.4
Current year 62.3
Extreme 62.3
103.4
1 year 58
Extreme 58
103.4
3 years 32.5
Extreme 32.5
103.4
5 years 32.5
Extreme 32.5
103.4
10 years 24.75
Extreme 24.75
103.4
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.04% - - 16.06B
+0.32%+0.24%+46.16%+136.37% 1,258B
-0.46%+5.44%+48.96%+90.60% 679B
-0.18%+2.06%+33.46%+110.61% 518B
+0.01%+2.43%+43.60%+69.17% 390B
-1.48%+0.99%+68.41%+44.10% 367B
+0.89%+2.21%+31.51%+60.27% 307B
-0.70%+1.31%+6.20%+38.16% 293B
-0.42%+0.15%+42.73%+72.82% 252B
+0.01%+0.50%+42.45%+121.69% 210B
Average -0.25%+1.05%+40.39%+82.64% 475B
Weighted average by Cap. -0.21%+1.18%+42.57%+95.26%

Financials

2026 *2027 *
Net sales 2.11B 2.36B 1.94B 1.76B 3.34B 221B 3.42B 23.2B 9.25B 118B 8.86B 8.67B 373B 2.41B 2.7B 2.22B 2.01B 3.81B 253B 3.91B 26.53B 10.57B 135B 10.13B 9.92B 427B
Net income 608M 681M 559M 507M 962M 63.81B 986M 6.69B 2.67B 34.16B 2.56B 2.5B 108B 711M 796M 654M 594M 1.13B 74.65B 1.15B 7.83B 3.12B 39.97B 2.99B 2.93B 126B
Net Debt -117M -131M -108M -97.84M -185M -12.3B -190M -1.29B -514M -6.59B -493M -482M -20.74B -377M -423M -347M -315M -597M -39.63B -612M -4.15B -1.66B -21.22B -1.59B -1.55B -66.83B
Projected Income Statement - Annual - Orion Oyj
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,215
Date Price Change Volume
10/11/26 €102.00 0.00% 16,968
09/11/26 €102.00 +0.99% 7,466
06/11/26 €101.00 0.00% 13,128
05/11/26 €101.00 +0.60% 8,044
04/11/26 €100.40 +1.62% 8,906
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Orion Oyj
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
102.20EUR
Average target price
87.50EUR
Spread / Average Target
-14.38%